Cargando…
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
BACKGROUND: Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas...
Autores principales: | Diessner, Joachim, Wischnewsky, Manfred, Blettner, Maria, Häusler, Sebastian, Janni, Wolfgang, Kreienberg, Rolf, Stein, Roland, Stüber, Tanja, Schwentner, Lukas, Bartmann, Catharina, Wöckel, Achim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167411/ https://www.ncbi.nlm.nih.gov/pubmed/27992550 http://dx.doi.org/10.1371/journal.pone.0168730 |
Ejemplares similares
-
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
por: Diessner, Joachim, et al.
Publicado: (2016) -
The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients
por: Stein, Roland Gregor, et al.
Publicado: (2016) -
Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
por: Ebner, Florian, et al.
Publicado: (2019) -
Effect of adjuvant radiotherapy in elderly patients with breast cancer
por: Stueber, Tanja Nadine, et al.
Publicado: (2020) -
Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study
por: Herr, Daniel, et al.
Publicado: (2019)